Lv1
80 积分 2026-01-27 加入
S2463 Targeting Liver and Glucose: Comparative Efficacy of SGLT2i and GLP-1RA in NAFLD Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis
1天前
求助中
Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes
1天前
求助中
Hepatic events associated with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a nationwide cohort study
1天前
已完结
Glucagon‐Like Peptide‐1 Receptor Agonists and Liver Outcomes in Patients With MASLD and Type 2 Diabetes
3天前
已完结
Relevance of GLP-1 receptor agonists or SGLT-2 inhibitors on the recruitment for clinical studies in patients with NAFLD
5天前
已完结
Liver gains beyond glycemic control: GLP-1 vs. SGLT2 in metabolic dysfunction–associated steatohepatitis (MASH): A real-world data analysis
8天前
已关闭
Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis
13天前
已完结
Trends in risk factor control and treatment among patients with non‐alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory‐wide study
14天前
已完结
Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis
1个月前
已完结
Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies
1个月前
已完结
皖公网安备34019202002308
